Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 289

Sort by

Sort Order Select

Journal Articles

Neighborhood Socioeconomic Disadvantage and Distance from Treatment Center Do Not Impact Survival Outcomes of Patients with Non-Hodgkin Lymphoma and Multiple Myeloma Treated with CAR T-Cell Therapies

Agrima Mian, Danai Dima, Betty K. Hamilton, Allison Winter, Jack Khouri, Louis S. Williams, Shahzad Raza, Deepa Jagadeesh, Aaron T. Gerds, Robert M. Dean, Matt Kalaycio, Claudio Brunstein, Craig S Sauter, Faiz Anwer, Brian T. Hill, Paolo Caimi

Blood (2023) 142 (Supplement 1): 7399.

https://doi.org/10.1182/blood-2023-188712

Published: 2023

Journal Articles

Day 100 Risk Assessment Tool Predicts 1 Year Survival in Allogeneic Hematopoietic Cell Transplant Patients

Joseph Farinella, Lauren M Granat, Hong Li, Sharon M Caroniti, Pranay S. Hegde, Matt Kalaycio, Ronald Sobecks, Claudio Brunstein, Craig S Sauter, Betty K. Hamilton

Blood (2023) 142 (Supplement 1): 3725.

https://doi.org/10.1182/blood-2023-189629

Published: 2023

Journal Articles

Influence of Pre-Transplant Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation

Ronald Sobecks, Hong Li, Danielle Cenin, Seema Patel, Jesse Edwards, Stephanie Farlow, Amelia Bragg, Rabi Hanna, Seth J Rotz, Deepa Jagadeesh, Aaron T. Gerds, Robert M. Dean, Brad Pohlman, Betty K. Hamilton, Claudio Brunstein, Matt Kalaycio, Craig S Sauter

Blood (2023) 142 (Supplement 1): 3621.

https://doi.org/10.1182/blood-2023-187071

Published: 2023

Journal Articles

Risk of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant

Hussein Awada, Adel Hajj Ali, Beth M. Faiman, Allison Winter, Sandra Mazzoni, Christy J. Samaras, Craig S. Sauter, Willem J. van Heeckeren, Robert M. Dean, Brad Pohlman, Brian T. Hill, Jason Valent, Ronald M. Sobecks, Louis S. Williams, Deepa Jagadeesh, Betty K. Hamilton, Matt Kalaycio, Faiz Anwer, Jack Khouri

Blood (2022) 140 (Supplement 1): 10596–10597.

https://doi.org/10.1182/blood-2022-168810

Published: 2022

Journal Articles

Long-Term Outcomes of Delayed Neutrophil Engraftment Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 12924–12925.

https://doi.org/10.1182/blood-2022-170385

Published: 2022

Journal Articles

Long-Term Outcomes of Autologous Hematopoietic Cell Transplant of Multiple Myeloma: A 10 Year Follow up Study

Blood (2022) 140 (Supplement 1): 12920–12921.

https://doi.org/10.1182/blood-2022-168262

Published: 2022

Journal Articles

Chip-Derived Vs De Novo Treatment-Related Myeloid Neoplasms after Autologous Stem Cell Transplant for Lymphoid Disorders

Hussein Awada, Carmelo Gurnari, Valeria Visconte, Teodora Kuzmanovic, Hassan Awada, James R. Cook, David S. Bosler, Brian J. Bolwell, Ronald M. Sobecks, Matt Kalaycio, Jaroslaw P. Maciejewski

Blood (2022) 140 (Supplement 1): 298–299.

https://doi.org/10.1182/blood-2022-167886

Published: 2022

Journal Articles

Siltuximab for First-Line Treatment of Cytokine Release Syndrome: A Response to the National Shortage of Tocilizumab

Seema Patel, Danielle Cenin, Donna Corrigan, Betty K. Hamilton, Matt Kalaycio, Ronald M. Sobecks, Faiz Anwer, Jack Khouri, Robert M. Dean, Allison Winter, Deepa Jagadeesh, Brad Pohlman, Brian T. Hill, Craig S. Sauter, Paolo F. Caimi

Blood (2022) 140 (Supplement 1): 5073–5074.

https://doi.org/10.1182/blood-2022-169809

Published: 2022

Journal Articles

The Role of Corrected Dlco in Predicting Relapse and Mortality Post Autologous Hematopoietic Cell Transplantation in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 10592–10593.

https://doi.org/10.1182/blood-2022-168433

Published: 2022

Journal Articles

Post-Transplant Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia

Leland Metheny, III, Ronald M. Sobecks, Christina Cho, Paolo F. Caimi, Navneet S. Majhail, Folashade Otegbeye, Kirsten M Boughan, Brenda W. Cooper, Erin Galloway, Molly Gallogly, Ehsan Malek, Benjamin Tomlinson, Aaron T. Gerds, Betty K. Hamilton, Matt Kalaycio, Sergio A Giralt, Marcos J.G. de Lima

Blood (2021) 138 (Supplement 1): 2899.

https://doi.org/10.1182/blood-2021-153041

Published: 2021

Journal Articles

Randomized Trial of Tacrolimus and Methotrexate Versus Tacrolimus, Reduced Dose Methotrexate, and Mycophenolate Mofetil for Prevention of Graft-Versus-Host Disease after Myeloablative Related and Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Betty K. Hamilton, Lisa A. Rybicki, Taylor Lucas, Donna Corrigan, Matt Kalaycio, Rabi Hanna, Seth J Rotz, Robert M. Dean, Aaron T. Gerds, Brian T. Hill, Deepa Jagadeesh, Brad Pohlman, Edward A. Copelan, Navneet S. Majhail

Blood (2021) 138 (Supplement 1): 99.

https://doi.org/10.1182/blood-2021-149686

Published: 2021

Journal Articles

Venous Thromboembolism Is Associated with Inferior Survival after Allogeneic Hematopoietic Cell Transplant

Lauren M. Granat, Lisa A. Rybicki, Mailey L. Wilks, Christina Ferraro, Matt Kalaycio, Ronald M. Sobecks, Navneet S. Majhail, Dana E. Angelini, Betty K. Hamilton

Blood (2021) 138 (Supplement 1): 4866.

https://doi.org/10.1182/blood-2021-151230

Published: 2021

Journal Articles

Resource Utilization and Factors Prolonging Hospitalization for Patients with Relapsed and Refractory Large B-Cell Lymphoma Receiving Tisagenlecleucel Versus Axicabtagene Ciloleucel

Agrima Mian, MBBS, MD, Wei Wei, MS, Brian T. Hill, MD, Betty K. Hamilton, MD, Allison M. Winter, MD, Jack Khouri, MD, Brad Pohlman, MD, Deepa Jagadeesh, MDMPH, Alex V. Mejia Garcia, MD, Faiz Anwer, MD, Aaron T. Gerds, MDMS, Matt Kalaycio, MD, Robert M. Dean, MD, Ronald Sobecks, MD, Navneet S. Majhail, MD MS

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-137801

Published: 2020

Journal Articles

Abnormal Metaphase Cytogenetics Adds to Currently Known Risk-Factors for Venous Thromboembolism in Multiple Myeloma: Derivation of the PRISM score

Rajshekhar Chakraborty, MD, Lisa Rybicki, MS, Jason Valent, MD, Alex V. Mejia Garcia, MD, Beth M. Faiman, PhDCNP, Jack Khouri, MD, Nathaniel Rosko, PharmD, Christy J. Samaras, DO, Matt Kalaycio, MD, Faiz Anwer, MD, Alok A Khorana, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-137525

Published: 2020

Journal Articles

Results of a Phase I Trial of Lenalidomide, Rituximab (R 2 ) and Ixazomib for Frontline Treatment of High Risk Follicular and Indolent Non-Hodgkin Lymphoma

Brian T. Hill, MD, Deepa Jagadeesh, MDMPH, Alex V. Mejia Garcia, MD, Robert M. Dean, MD, Omer N. Koc, MD, Matt Kalaycio, MD, Kirsten M Boughan, DO, Brenda W. Cooper, MD, Allison M. Winter, MD, Wesam B. Ahmed, MD, Brad Pohlman, MD, Christopher D'Andrea, PA-C, Kelsey Holkovic, RN, Ashley Morrison, RN, Paolo Caimi, MD, Mitchell Smith, MDPhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-136370

Published: 2020

Journal Articles

Hematopoietic Progenitor Cell Mobilization and Collection for Autologous Hematopoietic Cell Transplantation in AL Amyloidosis: A Single Center Experience

Anne K Hubben, MD, Lisa Rybicki, MS, Kristin Ricci, MD, Navneet S. Majhail, MD MS, Matt Kalaycio, MD, Betty K. Hamilton, MD, Brian T. Hill, MD, Allison M. Winter, MD, Brad Pohlman, MD, Deepa Jagadeesh, MDMPH, Faiz Anwer, MD, Robert M. Dean, MD, Ronald Sobecks, MD, Chakra P Chaulagain, MD, Hien D. Liu, MD, Jack Khouri, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-140456

Published: 2020

Journal Articles

Comparison of Outcomes and Quality-of-Life Measures Following Haploidentical Vs. Matched Related/Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Sanghee Hong, MD, Lisa Rybicki, MS, Linda McLellan, LISW, Jane Dabney, LISW-S, Aaron T. Gerds, MDMS, Seth J Rotz, MD, Matt Kalaycio, MD, Rabi Hanna, MD, Betty K. Hamilton, MD, Navneet S. Majhail, MD MS, Ronald Sobecks, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-138939

Published: 2020

Journal Articles

Targeted Treatment and Survival Following Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and MDS in the Contemporary Era

Sanghee Hong, MD, Lisa Rybicki, MS, Donna Corrigan, Betty K. Hamilton, MD, Ronald Sobecks, MD, Matt Kalaycio, MD, Robert M. Dean, MD, Brian T. Hill, MD, Brad Pohlman, MD, Deepa Jagadeesh, MDMPH, Faiz Anwer, MD, Navneet S. Majhail, MD MS

Blood (2019) 134 (Supplement_1): 4567.

https://doi.org/10.1182/blood-2019-124533

Published: 2019

Journal Articles

Interactions between Donor Activating Killer Immunoglobulin-like Receptors (KIRs) and Somatic Mutations and Their Association with Outcomes after Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia (AML)

Blood (2019) 134 (Supplement_1): 4599.

https://doi.org/10.1182/blood-2019-131011

Published: 2019

Journal Articles

Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat Analysis

Agrima Mian, MBBS, MD, Wei Wei, MS, Allison M. Winter, MD, Jack Khouri, MD, Deepa Jagadeesh, MDMPH, Faiz Anwer, MD, Aaron T. Gerds, MD MS, Robert M. Dean, MD, Ronald Sobecks, MD, Brad Pohlman, MD, Matt Kalaycio, MD, Betty K. Hamilton, MD, Navneet S. Majhail, MD MS, Brian T. Hill, MD

Blood (2019) 134 (Supplement_1): 4452.

https://doi.org/10.1182/blood-2019-127087

Published: 2019

NARROW

Neighborhood Socioeconomic Disadvantage and Distance from Treatment Center Do Not Impact Survival Outcomes of Patients with Non-Hodgkin Lymphoma and Multiple Myeloma Treated with CAR T-Cell Therapies

Day 100 Risk Assessment Tool Predicts 1 Year Survival in Allogeneic Hematopoietic Cell Transplant Patients

Influence of Pre-Transplant Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation

Risk of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant

Long-Term Outcomes of Delayed Neutrophil Engraftment Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma

Long-Term Outcomes of Autologous Hematopoietic Cell Transplant of Multiple Myeloma: A 10 Year Follow up Study

Chip-Derived Vs De Novo Treatment-Related Myeloid Neoplasms after Autologous Stem Cell Transplant for Lymphoid Disorders

Siltuximab for First-Line Treatment of Cytokine Release Syndrome: A Response to the National Shortage of Tocilizumab

The Role of Corrected Dlco in Predicting Relapse and Mortality Post Autologous Hematopoietic Cell Transplantation in Multiple Myeloma

Post-Transplant Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia

Randomized Trial of Tacrolimus and Methotrexate Versus Tacrolimus, Reduced Dose Methotrexate, and Mycophenolate Mofetil for Prevention of Graft-Versus-Host Disease after Myeloablative Related and Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Venous Thromboembolism Is Associated with Inferior Survival after Allogeneic Hematopoietic Cell Transplant

Resource Utilization and Factors Prolonging Hospitalization for Patients with Relapsed and Refractory Large B-Cell Lymphoma Receiving Tisagenlecleucel Versus Axicabtagene Ciloleucel

Abnormal Metaphase Cytogenetics Adds to Currently Known Risk-Factors for Venous Thromboembolism in Multiple Myeloma: Derivation of the PRISM score

Results of a Phase I Trial of Lenalidomide, Rituximab (R 2 ) and Ixazomib for Frontline Treatment of High Risk Follicular and Indolent Non-Hodgkin Lymphoma

Hematopoietic Progenitor Cell Mobilization and Collection for Autologous Hematopoietic Cell Transplantation in AL Amyloidosis: A Single Center Experience

Comparison of Outcomes and Quality-of-Life Measures Following Haploidentical Vs. Matched Related/Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Targeted Treatment and Survival Following Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and MDS in the Contemporary Era

Interactions between Donor Activating Killer Immunoglobulin-like Receptors (KIRs) and Somatic Mutations and Their Association with Outcomes after Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia (AML)

Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only